

Jonathan M Meyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1098089/publications.pdf>

Version: 2024-02-01

43
papers

1,598
citations

489802

18
h-index

488211

31
g-index

46
all docs

46
docs citations

46
times ranked

1447
citing authors

#	ARTICLE	IF	CITATIONS
1	Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. <i>CNS Spectrums</i> , 2022, 27, 208-217.	0.7	23
2	Weight Gain and Comorbidities Associated with Oral Second-Generation Antipsychotics: Analysis of Patients with Bipolar I Disorder or Schizophrenia. <i>CNS Spectrums</i> , 2022, 27, 240-240.	0.7	0
3	Weight Gain and Treatment Interruptions with Second-Generation Oral Antipsychotics: Analysis of Patients with Schizophrenia or Bipolar I Disorder. <i>CNS Spectrums</i> , 2021, 26, 160-160.	0.7	0
4	Clinician-Reported Patient Awareness of Symptoms and Severity of Tardive Dyskinesia in Patients Prescribed VMAT2 Inhibitors. <i>CNS Spectrums</i> , 2021, 26, 151-151.	0.7	0
5	Haloperidol and Haloperidol Decanoate. , 2021, , 157-173.		0
6	Tracking Oral Antipsychotic Adherence. , 2021, , 87-113.		0
7	Important Concepts about Second-Generation Antipsychotics. , 2021, , 241-248.		0
8	Level Interpretation Including Laboratory Reporting Issues, Responding to High Plasma Levels, Special Situations (Hepatic Dysfunction, Renal Dysfunction and Hemodialysis, Bariatric Surgery). , 2021, , 60-86.		0
9	Fluphenazine and Fluphenazine Decanoate. , 2021, , 174-189.		0
10	Amisulpride, Asenapine, Lurasidone, Brexpiprazole, Cariprazine. , 2021, , 337-371.		0
11	The Therapeutic Threshold and the Point of Futility. , 2021, , 34-59.		0
12	What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability. , 2021, , 114-146.		0
13	Sampling Times for Oral and Long-Acting Injectable Agents. , 2021, , 13-33.		0
14	A survey of personnel and services offered in 32 outpatient US clozapine clinics. <i>BMC Psychiatry</i> , 2021, 21, 583.	1.1	2
15	Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. <i>CNS Spectrums</i> , 2020, 25, 323-330.	0.7	15
16	Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. <i>CNS Spectrums</i> , 2020, 25, 136-144.	0.7	12
17	The Cal-DSH diversion guidelines. <i>CNS Spectrums</i> , 2020, 25, 701-713.	0.7	0
18	A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	13

#	ARTICLE	IF	CITATIONS
19	<p>Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2537-2550.	1.0	20
20	27 A New Method for Initiating Treatment with the Long-acting Antipsychotic Aripiprazole Lauroxil. CNS Spectrums, 2019, 24, 188-189.	0.7	2
21	Future directions in tardive dyskinesia research. Journal of the Neurological Sciences, 2018, 389, 76-80.	0.3	10
22	Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectrums, 2017, 22, 14-28.	0.7	191
23	Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Annals of General Psychiatry, 2017, 16, 36.	1.2	13
24	Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. Case Reports in Psychiatry, 2016, 2016, 1-7.	0.2	10
25	Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectrums, 2016, 21, 13-24.	0.7	191
26	Psychopharmacology of Persistent Violence and Aggression. Psychiatric Clinics of North America, 2016, 39, 541-556.	0.7	28
27	Weight change during long-term treatment with lurasidone. International Clinical Psychopharmacology, 2015, 30, 342-350.	0.9	30
28	The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Research, 2014, 218, 201-208.	1.7	11
29	A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectrums, 2014, 19, 432-438.	0.7	20
30	Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectrums, 2013, 18, 55-68.	0.7	24
31	Antipsychotics and Metabolics in the Post-CATIE Era. Current Topics in Behavioral Neurosciences, 2010, 4, 23-42.	0.8	32
32	Lurasidone: a new drug in development for schizophrenia. Expert Opinion on Investigational Drugs, 2009, 18, 1715-1726.	1.9	115
33	The Moderating Impact of Ethnicity on Metabolic Outcomes During Treatment With Olanzapine and Aripiprazole in Patients With Schizophrenia. Journal of Clinical Psychiatry, 2009, 70, 318-325.	1.1	29
34	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophrenia Research, 2008, 101, 273-286.	1.1	258
35	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophrenia Research, 2008, 103, 104-109.	1.1	64
36	Sexual Dysfunction in Patients Treated With Atypical Antipsychotics. Journal of Clinical Psychiatry, 2008, 69, e26.	1.1	57

#	ARTICLE	IF	CITATIONS
37	Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 1, 28-33.	1.1	4
38	Antipsychotic safety and efficacy concerns. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 14, 20-6.	1.1	8
39	Prevalence of the Metabolic Syndrome in Veterans with Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2006, 12, 5-10.	0.3	43
40	Bone Mineral Density in Male Schizophrenia Patients: A Review. <i>Annals of Clinical Psychiatry</i> , 2006, 18, 43-48.	0.6	24
41	Lithium toxicity after switch from fosinopril to lisinopril. <i>International Clinical Psychopharmacology</i> , 2005, 20, 115-118.	0.9	31
42	A Retrospective Comparison of Weight, Lipid, and Glucose Changes Between Risperidone- and Olanzapine-Treated Inpatients. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 425-433.	1.1	218
43	Individual Changes in Clozapine Levels After Smoking Cessation: Results and a Predictive Model. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 569-574.	0.7	95